These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 22046716)

  • 21. Implementing rotavirus vaccination in Asia.
    Santosham M; Nelson EA; Bresee JS
    Vaccine; 2007 Nov; 25(44):7711-6. PubMed ID: 17881099
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries.
    Goldie SJ; O'Shea M; Campos NG; Diaz M; Sweet S; Kim SY
    Vaccine; 2008 Jul; 26(32):4080-93. PubMed ID: 18550229
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An update to "The cost-effectiveness of rotavirus vaccination: comparative analyses for five European countries and transferability in Europe".
    Jit M; Mangen MJ; Melliez H; Yazdanpanah Y; Bilcke J; Salo H; Edmunds WJ; Beutels P
    Vaccine; 2010 Nov; 28(47):7457-9. PubMed ID: 20846529
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Human papillomavirus vaccine: a paradigm shift for pediatricians.
    Jenson HB
    Curr Opin Pediatr; 2009 Feb; 21(1):112-21. PubMed ID: 19242247
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Health care costs of diarrheal disease and estimates of the cost-effectiveness of rotavirus vaccination in Vietnam.
    Fischer TK; Anh DD; Antil L; Cat ND; Kilgore PE; Thiem VD; Rheingans R; Tho le H; Glass RI; Bresee JS
    J Infect Dis; 2005 Nov; 192(10):1720-6. PubMed ID: 16235169
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mathematical models for predicting the epidemiologic and economic impact of vaccination against human papillomavirus infection and disease.
    Dasbach EJ; Elbasha EH; Insinga RP
    Epidemiol Rev; 2006; 28():88-100. PubMed ID: 16740585
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Integration of human papillomavirus vaccination, cytology, and human papillomavirus testing.
    Schiffman M
    Cancer; 2007 Jun; 111(3):145-53. PubMed ID: 17487850
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-effectiveness and potential impact of rotavirus vaccination in the United States.
    Widdowson MA; Meltzer MI; Zhang X; Bresee JS; Parashar UD; Glass RI
    Pediatrics; 2007 Apr; 119(4):684-97. PubMed ID: 17403839
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A critique of criteria for evaluating vaccines for inclusion in mandatory school immunization programs.
    Opel DJ; Diekema DS; Marcuse EK
    Pediatrics; 2008 Aug; 122(2):e504-10. PubMed ID: 18676536
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mathematical models of cervical cancer prevention in the Asia Pacific region.
    Goldie SJ; Diaz M; Kim SY; Levin CE; Van Minh H; Kim JJ
    Vaccine; 2008 Aug; 26 Suppl 12():M17-29. PubMed ID: 18945411
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Projected health benefits and costs of pneumococcal and rotavirus vaccination in Uganda.
    Tate JE; Kisakye A; Mugyenyi P; Kizza D; Odiit A; Braka F
    Vaccine; 2011 Apr; 29(17):3329-34. PubMed ID: 21241733
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rotavirus vaccines: the role of researchers in moving evidence to action.
    Wecker JR; Phillips DC; Hayes J
    Vaccine; 2009 Nov; 27 Suppl 5():F4-6. PubMed ID: 19931717
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anti-HPV vaccination: a review of recent economic data for Italy.
    Mennini FS; Costa S; Favato G; Picardo M
    Vaccine; 2009 May; 27 Suppl 1():A54-61. PubMed ID: 19480963
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Human papillomavirus (HPV) vaccines: a Canadian update.
    Foerster V; Murtagh J
    Issues Emerg Health Technol; 2007 Dec; (109):1-8. PubMed ID: 18062141
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Economic evaluation of the 7-vaccine routine childhood immunization schedule in the United States, 2001.
    Zhou F; Santoli J; Messonnier ML; Yusuf HR; Shefer A; Chu SY; Rodewald L; Harpaz R
    Arch Pediatr Adolesc Med; 2005 Dec; 159(12):1136-44. PubMed ID: 16330737
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-benefit analysis of a rotavirus immunization program in the Arab Republic of Egypt.
    Ortega O; El-Sayed N; Sanders JW; Abd-Rabou Z; Antil L; Bresee J; Mansour A; Adib I; Nahkla I; Riddle MS
    J Infect Dis; 2009 Nov; 200 Suppl 1():S92-8. PubMed ID: 19817621
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Economic burden of varicella in Singapore--a cost benefit estimate of implementation of a routine varicella vaccination.
    Jean-Jasmin LM; Lynette SP; Stefan M; Kai CS; Chew FT; Wah LB
    Southeast Asian J Trop Med Public Health; 2004 Sep; 35(3):693-6. PubMed ID: 15689089
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Benefits, cost requirements and cost-effectiveness of the HPV16,18 vaccine for cervical cancer prevention in developing countries: policy implications.
    Goldie SJ; O'Shea M; Diaz M; Kim SY
    Reprod Health Matters; 2008 Nov; 16(32):86-96. PubMed ID: 19027626
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Human papillomavirus vaccination: expected impacts and unresolved issues.
    Dempsey AF; Freed GL
    J Pediatr; 2008 Mar; 152(3):305-9. PubMed ID: 18280831
    [No Abstract]   [Full Text] [Related]  

  • 40. [Efficiency of human papillomavirus vaccination--estimates based on Dutch cost effectiveness analyses].
    Westra TA; Daemen T; Postma MJ; Wilschut JC
    Ned Tijdschr Geneeskd; 2009; 153():A356. PubMed ID: 19930733
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.